<DOC>
	<DOCNO>NCT02615223</DOCNO>
	<brief_summary>This trial go evaluate tumor control quality life patient prostate cancer treat endocrine therapy without cryoablation .</brief_summary>
	<brief_title>Endocrine Therapy With Without Cryoablation Stage IV Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine tumor control patient prostate cancer treat radiotherapy cryoablation - To determine quality life patient . OUTLINE : This multicenter study . Patients stratify accord Gleason score ( ≥ 8 v 7 v ≤ 6 ) , persistent prostatic specific antigen ( PSA ) allocation ( &gt; 0.5 ng/mL v ≤ 0.5 ng/mL ) , participate center . Patient allocate two treatment arm .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Prostate adenocarcinoma , T4N0M0 , Any T N+ M+ Previously untreated disease undergone endocrine therapy without reach castration resistant prostate cancer Survival ≥ 12 month WHO performance status 02 white blood cell ≥ 3.5 ×10*9/L Platelets ≥ 5×10*9/L Hemoglobin ≥ 10 g/dL History malignant disease History coronary artery disease Uncontrolled infection Other concurrent severe uncontrolled medical disease could compromise participation study ( i.e. , uncontrolled diabetes mellitus , uncontrolled cardiac disease , uncontrolled hypertension , congestive cardiac failure , ventricular arrhythmia , active ischemic heart disease , myocardial infarction within past six month , chronic liver renal disease , active upper gastrointestinal tract ulceration ) Psychological , familial , sociological , geographical condition potentially hamper compliance study treatment followup schedule</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>